Market Place
Sourcing Support
MediciNova Updates Ph 2/3 COMBAT-ALS Trial at ALS/MND Symposium
06 Dec 2024 //
GLOBENEWSWIRE
MediciNova CEO Yuichi Provides Corporate Update to Stockholders
19 Nov 2024 //
GLOBENEWSWIRE
MediciNova Gets Patent Allowance for MN-001 in Liver Triglyceride
14 Nov 2024 //
GLOBENEWSWIRE
MediciNova Faces Monetary Damages from Sanofi-Novartis Patent
11 Nov 2024 //
GLOBENEWSWIRE
MediciNova Updates Phase 2/3 Trial of MN-166 in ALS
23 Oct 2024 //
GLOBENEWSWIRE
MediciNova Supports NIH-Funded Trial For MN166 In ALS Patients
30 Sep 2024 //
GLOBENEWSWIRE
MediciNova`s MN-166 Abstract Accepted For Poster Presentation
09 Sep 2024 //
GLOBENEWSWIRE
MediciNova`s MN-166 in COMBAT-ALS Study to Present at NEALS 2024 Meeting
03 Sep 2024 //
GLOBENEWSWIRE
MediciNova Receives Patent Notice for MN-166 in Post-COVID Condition
29 Aug 2024 //
GLOBENEWSWIRE
MediciNova`s David Crean Takes On Investor And PR Communications Role
20 Jun 2024 //
GLOBENEWSWIRE
MediciNova`s MN-166 Glioblastoma Data At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
MediciNova: Two Poster Presentations On MN-001 For Cardiometabolic At EAS
28 May 2024 //
GLOBENEWSWIRE
MediciNova Allowed Patent Covers MN-166 Eye Cancer Metastasis Prevention
20 May 2024 //
GLOBENEWSWIRE
MediciNova to receive US patent ibudilast to treat chlorine-induced acute RDS
15 May 2024 //
PHARMABIZ
MediciNova Allowed Patent For MN-166 In Chlorine-Induced ARDS
14 May 2024 //
GLOBENEWSWIRE
MediciNova New MN-166 Patent For Extended-Release Formulation
07 May 2024 //
GLOBENEWSWIRE
MediciNova Announces Abstract of Trial ibudilast at the 2024 ASCO
02 Apr 2024 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166
26 Mar 2024 //
GLOBENEWSWIRE
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002
20 Mar 2024 //
GLOBENEWSWIRE
MediciNova Announces New Data and Results of MN-166
12 Mar 2024 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166
17 Jan 2024 //
GLOBENEWSWIRE
MediciNova Announces Abstract Regarding MN-166 in Lung Injury
21 Dec 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Decision to Grant for Patent Covering MN-166
06 Dec 2023 //
GLOBENEWSWIRE
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166
19 Nov 2023 //
GLOBENEWSWIRE
MediciNova`s Collaborator Initiates Development of a Gene Therapy Product
27 Oct 2023 //
GLOBENEWSWIRE
MediciNova Receives Allowance for Patent Covering the Combination of MN-166
10 Oct 2023 //
GLOBENEWSWIRE
MediciNova Receives Gene Therapy Milestone Payment
04 Oct 2023 //
GLOBENEWSWIRE
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166
27 Sep 2023 //
GLOBENEWSWIRE
MediciNova Announces Abstract Regarding MN-166 Accepted for Presentation
17 Aug 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Intention to Grant for a Patent Covering MN-166
16 Aug 2023 //
GLOBENEWSWIRE
MediciNova Receives a New Patent Covering MN-001
15 Aug 2023 //
GLOBENEWSWIRE
MediciNova Receives Notice of Intention to Grant for Patent MN-001 and MN-002
14 Aug 2023 //
GLOBENEWSWIRE
MediciNova Announces Presentation of Results from the Ph 2b Trial of MN-166
29 Jun 2023 //
GLOBENEWSWIRE
MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-166
14 May 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001
30 Apr 2023 //
GLOBENEWSWIRE
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166
09 Mar 2023 //
GLOBENEWSWIRE
MediciNova Announces Data Regarding MN-166 in Glioblastoma Tumor Tissue Analysis
20 Feb 2023 //
GLOBENEWSWIRE
MediciNova Announces Health Canada Grants Authorization to Evaluate MN-166
08 Feb 2023 //
GLOBENEWSWIRE
MediciNova Announces Completion of Enrollment in the Phase 2b Trial of MN 166
30 Jan 2023 //
GLOBENEWSWIRE
MediciNova Announces Completion of Enrollment in PII Trial Evaluating MN-166
12 Jan 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for Patent Covering MN-001 and MN-002
10 Jan 2023 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for Patent Covering MN-001 and MN-002
09 Jan 2023 //
GLOBENEWSWIRE
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of MN-166
05 Jan 2023 //
GLOBENEWSWIRE
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001
06 Dec 2022 //
GLOBENEWSWIRE
MediciNova Announces +Ve Results from Secondary Analysis of Ph2 Trial of MN-166
05 Dec 2022 //
GLOBENEWSWIRE
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
15 Sep 2022 //
GLOBENEWSWIRE
MediciNova Receives Issue Notification for a New Patent Covering MN-166
14 Sep 2022 //
GLOBENEWSWIRE
MediciNova Receives a Notice of Allowance for a New Patent MN-001 and MN-002
13 Sep 2022 //
GLOBENEWSWIRE
MediciNova enters deal to take part in long Covid treatment trial
17 Aug 2022 //
CLINICALTRIALSARENA
MediciNova to Participate in Grant-Funded Clinical Trial to Evaluate MN-166
16 Aug 2022 //
GLOBENEWSWIRE
MediciNova`s MN-001 Abstract Improves Serum Lipid Panel in T2D and NAFLD
09 Aug 2022 //
GLOBENEWSWIRE
MediciNova Announces Initiation of a PII Trial of MN-001 in NAFLD
26 Jul 2022 //
GLOBENEWSWIRE
MediciNova Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
21 Jul 2022 //
GLOBENEWSWIRE
MediciNova Announces Extension of BARDA Contract to Develop MN-166
29 Jun 2022 //
GLOBENEWSWIRE
MediciNova Announces MN-001 Research Collaboration with The Juntendo University
22 Jun 2022 //
GLOBENEWSWIRE
MediciNova Announces Positive Top-Line Results from PII Trial of MN-166
08 Jun 2022 //
GLOBENEWSWIRE
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
21 Apr 2022 //
GLOBENEWSWIRE
MediciNova Announces Publication of MN-166 Data
20 Apr 2022 //
GLOBENEWSWIRE
MediciNova Completes Enrollment in PII Trial of MN-166 in COVID-19 Patients
12 Apr 2022 //
GLOBENEWSWIRE
MediciNova Plans PII Trial of MN-001 in NAFLD with T2D & Hypertriglyceridemia
11 Apr 2022 //
GLOBENEWSWIRE
